1. Introduction {#s0005}
===============

Following tremendous advancement in pharmaceutical and medical research/technology, the use of biodegradable materials/polymers such as Poly ([dl]{.smallcaps}-Lactide-Co-Glycolide) (PLGA) nanoparticles/scaffolds/microparticles has become increasingly essential as a drug delivery system.

Examples include, inclusion of pharmaceutical excipient into polymeric matrices e.g. polymeric films, microsphere and nanospheres ([@b0005]), the use of nanoparticles containing therapeutic agents for site-targeted drug delivery and optimisation of drug treatment effects ([@b0010], [@b0025], [@b0015], [@b0020]) and use of an electrospun Active Pharmaceutical Ingredient (API)-loaded resorbable Poly Lactide (PLA) fibre for local periodontitis treatment ([@b0030], [@b0035], [@b0040]), etc.

PLGA has added advantages over other natural and synthetic polymers; it is biocompatible, it can be used to synthesise nano/micro-particles with tuneable physico-chemical properties and is an FDA (United States Food and Drug Administration) approved polymer ([@b0045], [@b0050], [@b0055]).

It not only increases the sustained release but also guards against enzymatic degradation of drugs. ([@b0060], [@b0065], [@b0215]).

The relevance of the characterisation of the interaction between polymer and drug(s) cannot be over emphasised because of its denotations on formulation outcomes, product integrity, drug-release kinetics as well as probable polymorphic transitions. ([@b0075], [@b0080], [@b0085], [@b0090], [@b0220], [@b0100], [@b0105], [@b0110]).

This is particularly important in the pharmaceutical drug development process where a drug product with optimal characteristics must be identified in the early stages in order to prevent unwanted 'surprises' in the later stages of development or after the drug has been approved for usage. ([@b0225], [@b0230]).

The type of formulations used during the various stages of drug development also determines the final properties of the drug product: for example when suspensions are used, particle size must be controlled as this can affect bioavailability. ([@b0125], [@b0130]).

The purpose of this study is to analyse the nature of the interaction (during microencapsulation) between three model drugs; metronidazole, paracetamol, sulphapyridine (shown in [Fig. 1](#f0005){ref-type="fig"}a--c respectively overleaf) and PLGA scaffolds using X-ray Powder Diffraction (XRPD).

XRPD was particularly chosen to monitor the encapsulation because of the superiority of the technique in differentiating between the structural properties of different materials. ([@b0135], [@b0140], [@b0235]).

More so all three drugs used in the study have reported crystal structures ([@b0150], [@b0155], [@b0160], [@b0240], [@b0170], [@b0175], [@b0180]) while the PLGA scaffold is amorphous thus making it easier to compare any changes that may arise in the X-ray patterns after encapsulation with already published data.

Scanning Electron Microscopy (SEM) was also used to probe the physical morphologies of the PLGA scaffolds before and after encapsulations in order to corroborate data from the XRPD studies.

2. Materials and methods {#s0010}
========================

PVA (fully hydrolysed) and sulphapyridine were purchased from Sigma Aldrich Co. 3050 Spruce Street, St. Louis, MO 63103 USA. PLGA was supplied by Evonik Degussa Corporation, 750 Lakeshore parkway, Birmingham, AL. 35211 USA. Metronidazole was procured from Nacalai Tesque Inc. Kyoto Japan; Paracetamol from R & M Marketing Essex, UK. HPLC grade Dichloromethane (DCM) was obtained from Fisher Scientific, Bishop Meadow road, Loughborough, UK, LE11 5RG. Distilled water was produced for this study using ELGA Purelab flex (Chemopharm Selangor, Malaysia), while Phosphate Buffered Saline (PBS, (pH 7.4)) tablets were supplied by Oxoid limited, Basingstoke, Hampshire, UK.

2.1. PLGA scaffolds preparation with drug encapsulation {#s0015}
-------------------------------------------------------

The PLGA scaffolds incorporated with the model drugs were prepared using the water in oil in water (w/o/w) emulsion technique ([@b0180]). 1 g of PLGA was weigh and dissolved in 5 ml of DCM, to this was added 250 μl of PBS solution (the model drugs were dissolved in separate 100 ml solutions of PBS at the following concentrations; metronidazole 0.5007% w/v, paracetamol 0.1409% w/v and sulphapyridine 0.09425 w/v according to their reported aqueous solubilities) ([@b0245], [@b0190], [@b0195]). The resulting mixture was homogenised (Silverson L5M-A) at 9000 rpm for 2 min. The new PLGA/DCM/PBS (plus model drug) mixture was then added to 200 ml of PVA solution which was then homogenised at 3000 rpm for 2 min. The double emulsion was then stirred for 2 min at 300 rpm and the microparticles formed were washed under a continuous flow of water in a sieve (Fisher test sieve number 230) and freeze dried.

2.2. XRPD analysis {#s0020}
------------------

XRPD patterns were collected on a Bruker D8 Advance diffractometer system (Bruker AXS, Madison, WI, USA), operating in a Bragg--Brentano geometry, at a wavelength (*λ*) of 1.54059 Å, 40 kV voltage, and a current of 40 mA (with a Cu Kα~1~ radiation source), using a LynxEye detector, samples were contained in flat Poly (methyl methacrylate) (PMMA) sample holder. Data acquisition was done at 0.025°/0.1 s step size over a total period of 5 min.

2.3. Scanning Electron Microscopy (SEM) {#s0025}
---------------------------------------

SEM images were obtained using the LEO 1450 (LEO Company LTD UK) variable pressure scanning electron microscope, at an accelerated voltage of 10 kV.

3. Results and discussion {#s0030}
=========================

[Figure 2a](#f0010){ref-type="fig"}, [Figure 2b](#f0015){ref-type="fig"}, [Figure 2c](#f0020){ref-type="fig"} show overlay plots of the XRPD patterns obtained before and after PLGA scaffold-drug encapsulation with metronidazole, paracetamol and sulphapyridine respectively.

Under ordinary visual inspection of [Figure 2a](#f0010){ref-type="fig"}, [Figure 2b](#f0015){ref-type="fig"}, [Figure 2c](#f0020){ref-type="fig"}, the changes in the XRPD patterns of the PLGA scaffolds are not obvious; but on closer inspection, weak peaks (∗) are evident on the X-ray patterns of the scaffolds after encapsulation even at the extremely low drug concentration used as shown in [Figure 3a](#f0025){ref-type="fig"}, [Figure 3b](#f0030){ref-type="fig"}, [Figure 3c](#f0035){ref-type="fig"} (black = PLGA scaffolds before encapsulation, green = PLGA scaffolds after encapsulation, in all cases); indicative of an interaction between the drugs and scaffolds.

While the appearance of new (weak) peaks is apparent in the encapsulated scaffolds as shown in [Figure 3a](#f0025){ref-type="fig"}, [Figure 3b](#f0030){ref-type="fig"}, [Figure 3c](#f0035){ref-type="fig"}, these peaks do not occur in regions where the pure drugs exhibit characteristic peaks i.e. 12.15°, 13.80° (metronidazole), 23.40°, 24.34° (paracetamol) and 19.59°, 24.78° (sulphapyridine).

As such, these said peaks cannot be attributed to a physical interaction between the drugs and the scaffolds. ([@b0245], [@b0190], [@b0195], [@b0200], [@b0205], [@b0210]).

Similarly, [Fig. 4](#f0040){ref-type="fig"}a--d below show the SEM images of the PLGA scaffolds before and after encapsulation with the model drugs used in this study.

[Fig. 4](#f0040){ref-type="fig"} above clearly shows that there is an interaction between the PLGA scaffold and the model drugs as the scaffolds are markedly different before and after encapsulation.

In conclusion, it has been shown that metronidazole, paracetamol and sulphapyridine can be encapsulated into PLGA scaffolds even at low concentration as permitted by their aqueous solubilities. XRPD has proven to be a veritable tool for monitoring the observed encapsulation, although the appearance of new/weaker peaks in the X-ray patterns of the encapsulated scaffolds cannot be adduced to a physical interaction between the drugs and scaffold rather it is suggestive of a stronger chemical interplay. SEM images also support the deductions from the study, with the physical appearances of the PLGA scaffolds significantly different after encapsulation.

The authors would like to thank Dr. Jonathan Burley (School of Pharmacy, University of Nottingham, United Kingdom) and Miss Lazo Muhammad (Department of Mathematics and Natural Science, American University of Iraq, Sulaimani) for their assistance with the study and the European Commission (as part of the 7th Framework Programme) for funding.

Peer review under responsibility of King Saud University.

![Molecular structures of metronidazole (a), paracetamol (b) and sulphapyridine (c).](gr1){#f0005}

![XRPD patterns of PLGA scaffolds before (black), after encapsulation (green) and pure metronidazole (blue).](gr2a){#f0010}

![XRPD patterns of PLGA scaffolds before (black), after (green) encapsulation and pure paracetamol (orange).](gr2b){#f0015}

![XRPD patterns of PLGA scaffolds before (black), after (green) encapsulation and pure sulphapyridine (cyan).](gr2c){#f0020}

![XRPD offset patterns of metronidazole encapsulation.](gr3a){#f0025}

![XRPD offset patterns for paracetamol encapsulation.](gr3b){#f0030}

![XRPD offset patterns for sulphapyridine encapsulation.](gr3c){#f0035}

![SEM images of PLGA scaffold before encapsulation (a) and after encapsulation with (b) metronidazole (c) paracetamol and (d) sulphapyridine (scale and magnification were 10 μm and 500× in all cases respectively).](gr4){#f0040}
